Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Hepatobiliary Diseases
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1510230

Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogues plus polyethylene glycol interferon

Provisionally accepted
yan peng yan peng 1,2mingzhe ma mingzhe ma 1,2ting liu ting liu 1,2wenmin he wenmin he 3shutao lin shutao lin 3*wa zhong wa zhong 1,2*xiaohui min xiaohui min 1,2*
  • 1 Sun Yat-sen University, Guangzhou, China
  • 2 Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong Province, China
  • 3 Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University, shenshan, China

The final, formatted version of the article will be published soon.

    The minority of the chronic hepatitis B (CHB) patients received polyethylene glycol interferon (PEG-IFN) combined with nucleotide analogues (NAs) can obtain hepatitis B surface antigen(HBsAg) clearance. In order to find out the advantaged population, we retrospectively collected 122 CHB patients treated with NAs alone or NAs plus PEG-IFN for 48 weeks, who were admitted to Sun Yat-Sen Memorial Hospital from 2019-2024. We found HBsAg clearance rate in NAs plus PEG-IFN group was 40.98%, which was significantly higher than that in the NAs group. Thus, NAs plus PEG-IFN therapy served as a relatively ideal regimen and the patients received combined treatment were then incorporated for further analysis for searching efficacy predictors.Through using univariate and multivariate analysis, we confirmed the predictive value of HBsAg, alanine aminotransferase(ALT) at week 24, and ALT change values from baseline to week 24. The area under the receiver operating characteristic (ROC) curve of each indicators ranged from 0.663 to 0.982. In conclusion, our study verified the clinical value of NAs plus PEG-IFN for treating CHB patients. Moreover, for the first time, we found ALT change values from baseline to week 24 (dALT2) could act as a novel independent clinical efficacy predictors in the forementioned population.

    Keywords: Nucleoside analogues, Pegylated interferon, HBeAg-negative, Chronic hepatitis B, HBsAg clearance

    Received: 16 Oct 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 peng, ma, liu, he, lin, zhong and min. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    shutao lin, Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University, shenshan, China
    wa zhong, Sun Yat-sen University, Guangzhou, China
    xiaohui min, Sun Yat-sen University, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.